A qualitative study led by researchers yielded nine patient-driven recommendations across circumstances that include changes to insurance, supportive services and financial assistance to reduce long-term, breast cancer-related economic burden.
The study has been published in the journal Cancer.
U.S. breast cancer patients experience considerable economic burdens compared with those who have other types of cancer.
The financial burdens are often exacerbated for patients who are managing treatment side effects, particularly breast cancer-related lymphedema, swelling of the arms or torso commonly caused by the removal of the lymph nodes during breast cancer surgery.
Over 250,000 new breast cancer cases are diagnosed each year in the U.S.
Lymphedema affects nearly 35 percent of U.S. breast cancer survivors and results in an estimated $14,877 in out-of-pocket costs in the first two years of a patient's diagnosis.
Previous research suggests that 10 years post-diagnosis, breast cancer survivors with lymphedema have over double the health care costs as those not affected by lymphedema.
"No one should have to make a choice between their health and their money. Yet breast cancer survivors face incredibly high prices that can lead to severe financial hardships, even bankruptcy," said lead author Lorraine T. Dean, ScD, assistant professor in the Bloomberg School's Department of Epidemiology. "These recommendations offer ways to adapt a range of policies and practices that would make it more likely that breast cancer survivors can afford and attain the care they need."
Previous studies of breast cancer patients focused on provider and insurer perspectives on reducing costs, but not the patient, noted Dean. "This study offered breast cancer survivors a voice to tell us what they think should be done to make their lives better."
For the study, interviews were conducted with 40 long-term breast cancer survivors from New Jersey and Pennsylvania in 2015.
Participants were chosen to ensure a range of ages, lifestyles and severity of lymphedema.
Of the 40 participants, 24 had lymphedema.
The interviews were designed to better understand the financial problems participants faced after cancer, what types of issues they may have had with insurers, who they asked for help and what they thought should happen so that future breast cancer survivors could avoid high costs.
The interviewees offered nine actionable recommendations:
Previous recommendations included affordable insurance, prompt information on costs and access to financial navigation and peer support.
In this study, recommendations include institutional changes and policies that patients see as setting or driving costs.
Patient-driven recommendations to keep insurance costs low have been criticised for potentially driving up costs for insurers.
As a counterargument, the authors offered an example: In one state, expanding coverage for lymphedema services and treatment lowered patient out-of-pocket costs and lymphedema-related hospitalisations, while having a less than 0.1 percent impact on costs for insurance claims and less than a 0.2 percent impact on insurance premiums after 10 years.
Several states (California, Louisiana, Maryland, North Carolina and Virginia) have passed legislation that expands lymphedema treatment coverage under existing insurance.
Congress has considered, but not yet passed, legislation that would do the same across the nation.
Survey participants offered several ideas for changes to private business services and nonprofits.
For example, mortgage deferment services, which are currently used for other reasons besides health, could be used to reduce expenses that could then be used for cancer treatment.
While many non-profits currently have charitable assistance programs, study participants suggested that eligibility for assistance be determined by whether or not the patient has access to additional resources, rather than on poverty guidelines.
Additionally, physicians and health providers could make referrals for financial counselling services during the course of care.
The researchers suggested that without changes, the out-of-pocket costs will continue to pose a challenge for the growing number of breast cancer survivors in the U.S.